Senores Pharmaceuticals Limited
| Opening Date | Closing Date | Face Value | Issue Price | Lot Size | Listing At | Total Issue Size | Basis of Allotment | Initiation of Refunds | Credit of Shares to Demat | Listing Date |
|---|---|---|---|---|---|---|---|---|---|---|
| 19-12-2024 | 23-12-2024 | ₹10 per share | 391 | 38 Shares | BSE, NSE | 1,48,87,723 shares (aggregating up to ₹582.11 Cr) | 2024-12-25 18:30:00 | 2024-12-26 18:30:00 | 2024-12-26 18:30:00 | 29-12-2024 |
About The Company
Senores Pharmaceuticals IPO is a book built issue of Rs 582.11 crores. The issue is a combination of fresh issue of 1.28 crore shares aggregating to Rs 500.00 crores and offer for sale of 0.21 crore shares aggregating to Rs 82.11 crores.
Senores Pharmaceuticals IPO opens for subscription on December 20, 2024 and closes on December 24, 2024. The allotment for the Senores Pharmaceuticals IPO is expected to be finalized on Thursday, December 26, 2024. Senores Pharmaceuticals IPO will list on BSE, NSE with tentative listing date fixed as Monday, December 30, 2024.
Senores Pharmaceuticals IPO price band is set at ₹372 to ₹391 per share. The minimum lot size for an application is 38. The minimum amount of investment required by retail investors is ₹14,858. The minimum lot size investment for sNII is 14 lots (532 shares), amounting to ₹2,08,012, and for bNII, it is 68 lots (2,584 shares), amounting to ₹10,10,344.
Equirus Capital Private Limited, Ambit Private Limited, Nuvama Wealth Management Limited are the book running lead managers of the Senores Pharmaceuticals IPO, while Link Intime India Private Ltd is the registrar for the issue.
Financials
| Period Ended | Total Assets | Total Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrow |
|---|---|---|---|---|---|---|
| 30-03-2022 | 59 | 15 | 1 | 36.59 | 25.37 | 14.21 |
| 30-03-2023 | 131 | 39 | 8 | 45.5 | 35.25 | 60.76 |
| 30-03-2024 | 622 | 217 | 33 | 231.71 | 175.94 | 348.38 |
| 29-09-2024 | 678 | 184 | 24 | 319.06 | 263.36 | 242.03 |
IPO Subscription Status
| Category | Subscription Times |
|---|---|
| Anchor Investors | 1 |
| Qualified Institutions | 97.84 |
| Non-Institutional Buyers | 100.356 |
| Retail | 93.16 |
| Total | 97.86 |
IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | 4858 |
| Retail (Max) | 13 | 494 | 191154 |
| S-HNI (Min) | 14 | 352 | 208013 |
| S-HNI (Max) | 67 | 2546 | 995486 |
| B-HNI (Min) | 68 | 2584 | 1010344 |
IPO Listing Details
| Listing Date | 29-12-2024 |
| BSE Script Code | 544319 |
| NSE Symbol | SENORES |
| ISIN | INE0RB801010 |
| Final Issue Price | 391 |
Promoter holdings
Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot.
Contact Information of the Company
Senores Pharmaceuticals Limited
1101 to 1103, 11th floor,
South Tower, ONE 42 oppositeJayantilal Park,
Ambali Bopal Road, Ahmedabad,-380054
Phone: +91-79-29999857
Email: cs@senorespharma.com
Website: https://senorespharma.com/
IPO Registrar
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: senorespharma.ipo@linkintime.co.in
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
IPO Lead Manager
Equirus Capital Private Limited (Past IPO Performance) Ambit Private Limited (Past IPO Performance) Nuvama Wealth Management Limited (Past IPO Performance)